Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
By J. Long, D. Holtzman. Cell, 2019
2,572 citations recorded by the source corpus.
Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiology. The presence of extracellular β-amyloid deposition as neuritic plaques and intracellular accumulation of hyperphosphorylated tau as neurofibrillary tangles remains the primary neuropathologic criteria for AD diagnosis. However, a number of recent fundamental discoveries highlight important pathological roles for other critical cellular and molecular processes. Despite this, no disease-modifying treatment currently exists, and numerous phase 3 clinical trials have failed to demonstrate benefits. Here, we review recent advances in our understanding of AD pathobiology and discuss current treatment strategies, highlighting recent clinical trials and opportunities for developing future disease-modifying therapies.
Subfields: Pharmacology, Physiology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/9231686941513e88e57650a734b2d4f1fcdbd4cb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
Citations in the corpus
- Hallmarks of neurodegenerative diseases. (2023, neutral): “…protein aggregation (1), synaptic and neuronal network dysfunction (2), aberrant proteostasis (3), cytoskeletal abnormalities (4), altered energy homeostasis (5), DNA and RNA defects (6), inflammation (7), and neuronal cell death (8). tetrabenazine that modulates dopaminergic signaling in HD chorea.”
- Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023, background): “123 Recently, genome-wide association studies (GWAS) have demonstrated that most AD risk genes are highly or exclusively in microglia, 124 suggesting that microglia play an essential role in AD development.”